Drug intelligence / Profile preview

1144U88 5'-triphosphate

Development stage: Unknown
Lead developer: Glaxo Wellcome
Modality: Small Molecules

Overview

1144U88 5'-triphosphate is the active intracellular metabolite of abacavir, a nucleoside reverse transcriptase inhibitor (NRTI) developed by Glaxo Wellcome (now GSK). It is a guanosine analog that, once formed, competes with natural nucleoside triphosphates and is incorporated into the nascent viral DNA strand. This incorporation leads to premature chain termination, thereby inhibiting the activity of HIV-1 reverse transcriptase and blocking viral replication. It is used in the treatment of HIV/AIDS as part of combination antiretroviral therapy.

Other names: (-)-carbovir

Targets

Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on 1144U88 5'-triphosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1144U88 5'-triphosphate.

Explore the full profile